Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

efizonerimod

An agonistic monoclonal antibody against receptor OX40 (CD134), with potential immunostimulatory activity. Upon administration, efizonerimod selectively binds to and activates the OX40 receptor, by mimicking the action of endogenous OX40 ligand (OX40L). OX40 receptor activation induces proliferation of memory and effector T lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor family, is expressed on T lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:efizonerimod alfa
immunoglobulin G4 (10-proline) (human heavy chain Fc fragment) fusion protein with tumor necrosis factor receptor-associated factor TRAF2 (human C-C domain fragment) fusion protein with CD252 antigen (human extracellular domain fragment), hexamer
Code name:MEDI6383
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search